Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 6 | 2024 | 232 | 1.630 |
Why?
|
| Opioid-Related Disorders | 4 | 2024 | 55 | 1.020 |
Why?
|
| Bayes Theorem | 8 | 2024 | 80 | 0.950 |
Why?
|
| Ohio | 6 | 2021 | 58 | 0.790 |
Why?
|
| Decision Making | 1 | 2023 | 194 | 0.740 |
Why?
|
| Patient Admission | 2 | 2019 | 58 | 0.680 |
Why?
|
| Research Design | 2 | 2023 | 315 | 0.640 |
Why?
|
| Population Surveillance | 1 | 2019 | 125 | 0.620 |
Why?
|
| Humans | 39 | 2024 | 32082 | 0.560 |
Why?
|
| Data Collection | 1 | 2015 | 181 | 0.500 |
Why?
|
| Diabetes Mellitus | 4 | 2022 | 412 | 0.480 |
Why?
|
| Adolescent | 11 | 2021 | 3568 | 0.470 |
Why?
|
| Adult | 18 | 2024 | 9375 | 0.450 |
Why?
|
| Substance-Related Disorders | 2 | 2024 | 128 | 0.430 |
Why?
|
| Male | 29 | 2024 | 19202 | 0.420 |
Why?
|
| Middle Aged | 18 | 2024 | 11834 | 0.420 |
Why?
|
| Female | 29 | 2024 | 19999 | 0.420 |
Why?
|
| Coronary Disease | 3 | 2022 | 211 | 0.380 |
Why?
|
| Young Adult | 9 | 2024 | 2665 | 0.370 |
Why?
|
| Hydrocortisone | 2 | 2021 | 57 | 0.360 |
Why?
|
| Length of Stay | 3 | 2019 | 312 | 0.340 |
Why?
|
| Upper Extremity | 2 | 2019 | 57 | 0.320 |
Why?
|
| Blood Glucose | 3 | 2020 | 494 | 0.320 |
Why?
|
| United States | 5 | 2024 | 3975 | 0.310 |
Why?
|
| Bacterial Infections | 2 | 2018 | 51 | 0.290 |
Why?
|
| Hepatitis C | 2 | 2024 | 42 | 0.280 |
Why?
|
| Prevalence | 4 | 2024 | 989 | 0.280 |
Why?
|
| Stroke | 3 | 2022 | 584 | 0.270 |
Why?
|
| Aged | 14 | 2021 | 10308 | 0.270 |
Why?
|
| Emergency Service, Hospital | 3 | 2019 | 467 | 0.270 |
Why?
|
| Heroin | 1 | 2024 | 21 | 0.240 |
Why?
|
| African Americans | 3 | 2021 | 1424 | 0.230 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2023 | 43 | 0.220 |
Why?
|
| Rural Population | 1 | 2024 | 277 | 0.210 |
Why?
|
| Hospitals, Pediatric | 2 | 2019 | 47 | 0.200 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 10 | 0.200 |
Why?
|
| Retrospective Studies | 8 | 2020 | 3505 | 0.180 |
Why?
|
| Prognosis | 3 | 2019 | 1496 | 0.180 |
Why?
|
| Child | 7 | 2020 | 2439 | 0.180 |
Why?
|
| Advance Care Planning | 1 | 2020 | 15 | 0.180 |
Why?
|
| Video Games | 1 | 2019 | 5 | 0.170 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2019 | 4 | 0.170 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2019 | 7 | 0.170 |
Why?
|
| Acute Disease | 2 | 2018 | 252 | 0.170 |
Why?
|
| Allostasis | 1 | 2019 | 12 | 0.170 |
Why?
|
| Capital Punishment | 1 | 2019 | 1 | 0.170 |
Why?
|
| Adiposity | 1 | 2021 | 198 | 0.170 |
Why?
|
| Insulin Resistance | 1 | 2022 | 461 | 0.170 |
Why?
|
| Aldosterone | 1 | 2019 | 26 | 0.170 |
Why?
|
| Suicide, Attempted | 1 | 2019 | 32 | 0.160 |
Why?
|
| Off-Label Use | 1 | 2019 | 12 | 0.160 |
Why?
|
| Sodium Channel Blockers | 1 | 2018 | 7 | 0.160 |
Why?
|
| Deep Brain Stimulation | 1 | 2019 | 49 | 0.160 |
Why?
|
| Myotonic Disorders | 1 | 2018 | 3 | 0.160 |
Why?
|
| Lethargy | 1 | 2018 | 2 | 0.160 |
Why?
|
| Anaphylaxis | 1 | 2019 | 12 | 0.160 |
Why?
|
| Consciousness Disorders | 1 | 2018 | 5 | 0.160 |
Why?
|
| Methicillin Resistance | 1 | 2019 | 22 | 0.160 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 2018 | 8 | 0.160 |
Why?
|
| Exercise Movement Techniques | 1 | 2018 | 3 | 0.160 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 39 | 0.160 |
Why?
|
| Muscular Diseases | 1 | 2018 | 22 | 0.160 |
Why?
|
| Staphylococcus aureus | 1 | 2019 | 53 | 0.160 |
Why?
|
| Paresis | 1 | 2018 | 12 | 0.160 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2018 | 4 | 0.160 |
Why?
|
| Child Abuse | 1 | 2019 | 27 | 0.160 |
Why?
|
| Foot | 1 | 2018 | 39 | 0.160 |
Why?
|
| Motor Neurons | 1 | 2018 | 40 | 0.160 |
Why?
|
| Cohort Studies | 5 | 2022 | 1816 | 0.160 |
Why?
|
| HIV Infections | 1 | 2023 | 395 | 0.160 |
Why?
|
| Polymerase Chain Reaction | 1 | 2019 | 198 | 0.160 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 25 | 0.160 |
Why?
|
| Office Visits | 1 | 2019 | 73 | 0.160 |
Why?
|
| Fever | 1 | 2018 | 60 | 0.160 |
Why?
|
| Age Factors | 5 | 2019 | 1187 | 0.160 |
Why?
|
| Child, Preschool | 5 | 2019 | 1267 | 0.150 |
Why?
|
| Parkinson Disease | 1 | 2019 | 87 | 0.150 |
Why?
|
| Muscle Contraction | 1 | 2018 | 112 | 0.150 |
Why?
|
| Pediatrics | 1 | 2020 | 155 | 0.150 |
Why?
|
| Staphylococcal Infections | 1 | 2019 | 77 | 0.150 |
Why?
|
| Longitudinal Studies | 4 | 2022 | 770 | 0.150 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2017 | 6 | 0.150 |
Why?
|
| Exercise Test | 1 | 2019 | 225 | 0.150 |
Why?
|
| Heart Diseases | 1 | 2019 | 115 | 0.150 |
Why?
|
| Dermatomyositis | 1 | 2017 | 19 | 0.150 |
Why?
|
| Myasthenia Gravis | 1 | 2017 | 15 | 0.150 |
Why?
|
| Myotonia Congenita | 1 | 2017 | 1 | 0.150 |
Why?
|
| Cardiovascular Agents | 1 | 2017 | 23 | 0.150 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 44 | 0.140 |
Why?
|
| Residence Characteristics | 1 | 2019 | 202 | 0.140 |
Why?
|
| Emergency Medical Services | 1 | 2019 | 177 | 0.140 |
Why?
|
| Prospective Studies | 5 | 2019 | 2282 | 0.130 |
Why?
|
| Atherosclerosis | 1 | 2022 | 766 | 0.130 |
Why?
|
| Depression | 1 | 2019 | 445 | 0.130 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 352 | 0.130 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 109 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 201 | 0.130 |
Why?
|
| Time Factors | 3 | 2019 | 2145 | 0.120 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 512 | 0.120 |
Why?
|
| Ribonucleases | 1 | 2012 | 4 | 0.110 |
Why?
|
| Proteus mirabilis | 1 | 2012 | 2 | 0.110 |
Why?
|
| Uropathogenic Escherichia coli | 1 | 2012 | 6 | 0.110 |
Why?
|
| Anti-Infective Agents | 1 | 2012 | 44 | 0.100 |
Why?
|
| Quality of Life | 1 | 2018 | 946 | 0.100 |
Why?
|
| Organogenesis | 1 | 2012 | 16 | 0.100 |
Why?
|
| Skin Tests | 1 | 2011 | 12 | 0.100 |
Why?
|
| Infant | 3 | 2019 | 1061 | 0.100 |
Why?
|
| Hypersensitivity | 1 | 2011 | 24 | 0.090 |
Why?
|
| Risk Factors | 4 | 2019 | 3880 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 1128 | 0.090 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 881 | 0.090 |
Why?
|
| Urinary Bladder | 1 | 2012 | 182 | 0.090 |
Why?
|
| Electromyography | 2 | 2018 | 59 | 0.080 |
Why?
|
| Hand Strength | 2 | 2018 | 101 | 0.070 |
Why?
|
| Respiratory Tract Infections | 2 | 2018 | 40 | 0.070 |
Why?
|
| Urinary Tract Infections | 2 | 2018 | 45 | 0.070 |
Why?
|
| Sex Factors | 2 | 2019 | 667 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 684 | 0.070 |
Why?
|
| Accidental Falls | 2 | 2019 | 221 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 1542 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2018 | 547 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2019 | 80 | 0.070 |
Why?
|
| Incidence | 2 | 2019 | 1199 | 0.060 |
Why?
|
| Drug Users | 1 | 2024 | 11 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 3990 | 0.060 |
Why?
|
| Appalachian Region | 1 | 2023 | 17 | 0.060 |
Why?
|
| Central Nervous System Stimulants | 1 | 2024 | 76 | 0.060 |
Why?
|
| Massachusetts | 1 | 2023 | 26 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2263 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2023 | 120 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2023 | 91 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2023 | 294 | 0.050 |
Why?
|
| Parathyroid Hormone | 1 | 2022 | 45 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 765 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 68 | 0.050 |
Why?
|
| Glucose | 1 | 2022 | 174 | 0.050 |
Why?
|
| Vitamin D | 1 | 2022 | 184 | 0.050 |
Why?
|
| Waist Circumference | 1 | 2021 | 90 | 0.050 |
Why?
|
| Intra-Abdominal Fat | 1 | 2021 | 63 | 0.050 |
Why?
|
| Saliva | 1 | 2020 | 36 | 0.040 |
Why?
|
| Adiponectin | 1 | 2021 | 106 | 0.040 |
Why?
|
| Glucose Intolerance | 1 | 2020 | 46 | 0.040 |
Why?
|
| Circadian Rhythm | 1 | 2020 | 43 | 0.040 |
Why?
|
| Fasting | 1 | 2020 | 95 | 0.040 |
Why?
|
| Algorithms | 1 | 2023 | 496 | 0.040 |
Why?
|
| Hemiplegia | 1 | 2019 | 13 | 0.040 |
Why?
|
| Documentation | 1 | 2020 | 46 | 0.040 |
Why?
|
| Mice | 2 | 2018 | 2474 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2017 | 3304 | 0.040 |
Why?
|
| Glasgow Coma Scale | 1 | 2019 | 27 | 0.040 |
Why?
|
| Mississippi | 1 | 2019 | 27 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 27 | 0.040 |
Why?
|
| Emergency Medical Service Communication Systems | 1 | 2019 | 3 | 0.040 |
Why?
|
| Stiff-Person Syndrome | 1 | 2018 | 1 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2019 | 98 | 0.040 |
Why?
|
| Myelin Proteins | 1 | 2018 | 4 | 0.040 |
Why?
|
| Torque | 1 | 2018 | 20 | 0.040 |
Why?
|
| Toes | 1 | 2018 | 14 | 0.040 |
Why?
|
| Gastroenteritis | 1 | 2018 | 12 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2018 | 42 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 105 | 0.040 |
Why?
|
| Muscle Weakness | 1 | 2018 | 37 | 0.040 |
Why?
|
| K562 Cells | 1 | 2018 | 5 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2019 | 240 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2019 | 292 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2019 | 90 | 0.040 |
Why?
|
| Neuromuscular Junction | 1 | 2018 | 66 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2020 | 406 | 0.040 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2018 | 62 | 0.040 |
Why?
|
| Animals | 3 | 2018 | 7510 | 0.040 |
Why?
|
| Poverty | 1 | 2019 | 115 | 0.040 |
Why?
|
| Triage | 1 | 2019 | 71 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2019 | 120 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 288 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 261 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2019 | 186 | 0.040 |
Why?
|
| Plasmapheresis | 1 | 2017 | 11 | 0.040 |
Why?
|
| Cause of Death | 1 | 2019 | 236 | 0.040 |
Why?
|
| Action Potentials | 1 | 2018 | 177 | 0.040 |
Why?
|
| Mortality | 1 | 2019 | 125 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2017 | 32 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 753 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 873 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 47 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 516 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 2016 | 17 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 122 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2019 | 673 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 594 | 0.030 |
Why?
|
| Pain | 1 | 2018 | 287 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 322 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2017 | 198 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 390 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 764 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 187 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 240 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 566 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 354 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 1020 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 629 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2019 | 1165 | 0.030 |
Why?
|
| Obesity | 1 | 2022 | 1176 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2019 | 473 | 0.030 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2012 | 14 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 98 | 0.030 |
Why?
|
| Heart Failure | 1 | 2019 | 639 | 0.030 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2012 | 4 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 247 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2012 | 50 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 2012 | 68 | 0.020 |
Why?
|
| Urothelium | 1 | 2012 | 55 | 0.020 |
Why?
|
| Antigens, Dermatophagoides | 1 | 2011 | 1 | 0.020 |
Why?
|
| Pyroglyphidae | 1 | 2011 | 1 | 0.020 |
Why?
|
| Antigens, Plant | 1 | 2011 | 3 | 0.020 |
Why?
|
| Trees | 1 | 2011 | 2 | 0.020 |
Why?
|
| Poaceae | 1 | 2011 | 2 | 0.020 |
Why?
|
| Organ Size | 1 | 2012 | 218 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 337 | 0.020 |
Why?
|
| Allergens | 1 | 2011 | 15 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 1427 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2012 | 132 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2012 | 398 | 0.020 |
Why?
|